指南与共识其他结缔组织病血管炎

抗磷脂综合征血栓与产科管理:EULAR推荐系统文献综述

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.
指南 / 共识 · RMD Open · 2019-04-28

该系统文献综述检索至2018年1月,纳入188篇文章,为EULAR成人抗磷脂综合征管理推荐提供依据。研究发现低剂量阿司匹林对高风险aPL无症状者预防血栓有保护作用,静脉血栓者INR 3-4与2-3无额外获益,三重aPL阳性者利伐沙班血栓复发率高于华法林,产科APS中LDA联合肝素优于单用LDA。

要点

  • 高风险aPL无APS者,低剂量阿司匹林对预防血栓有保护作用
  • 静脉或动脉血栓APS,INR 3-4较2-3无额外获益
  • 三重aPL阳性者利伐沙班血栓复发率高于华法林

核心结论

  • 需要设计良好、患者群体同质的研究来指导APS管理。

研究设计与样本

  • 系统文献综述检索至2018年1月,从7534篇文献(手工检索另加15篇)中纳入188篇。
  • 研究问题采用PICO格式构建,纳入报告各相关干预措施的文章。

主要发现

  • 两项Meta分析显示低剂量阿司匹林对无血栓或产科APS的高风险aPL个体预防血栓有保护作用。
  • 两项RCT和三项队列研究显示静脉血栓患者华法林目标INR 3-4较INR 2-3无额外获益。
  • 两项RCT和两项队列研究显示动脉血栓患者两种目标INR组复发血栓风险无差异。
  • 一项开放标签试验显示三重aPL阳性患者利伐沙班治疗血栓复发率高于华法林。
  • RCT和队列研究显示LDA联合肝素在多种产科APS中比单用LDA更有效。

关键数值与推荐

  • 静脉血栓患者:华法林目标INR 3-4对比INR 2-3无额外获益(基于2项RCT和3项队列研究)。
  • 动脉血栓患者:目标INR 3-4与INR 2-3复发血栓风险无差异(基于2项RCT和2项队列研究)。
  • 三重aPL阳性患者:利伐沙班血栓复发率高于华法林(基于1项开放标签试验)。
  • 产科APS:LDA联合肝素比单用LDA更有效(基于RCT和队列研究)。

临床怎么用

  • 对高风险aPL无APS个体可考虑低剂量阿司匹林预防血栓。
  • 静脉或动脉血栓APS患者抗凝目标INR 3-4不优于2-3。
  • 三重aPL阳性患者使用利伐沙班需警惕血栓复发风险高于华法林。
  • 产科APS治疗中LDA联合肝素优于单用LDA。

局限性

  • 系统文献综述结果受间接证据和一些治疗患者群体异质性限制。
  • 仅少数高质量RCT可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a systematic literature review (SLR) informing the European Lmmendations for the management of antiphospholipid syndrome (APS) in adults. METHODS: A SLR through January 2018 was performed. Research questions were constructed using the Patient, Intervention, Comparator, Outcome (PICO) format. We included data from articles that reported on each relevant intervention. Summary effect estimates were calculated for direct comparison studies that matched the PICO question exactly, and for studies with the relevant intervention and comparator. When meta-analyses were available, we used these estimates. RESULTS: From 7534 retrieved articles (+15 from hand searches), 188 articles were included in the review. In individuals with high-risk antiphospholipid antibody (aPL) profile without prior thrombotic or obstetric APS, two meta-analyses showed a protective effect of low-dose aspirin (LDA) against thrombosis. Two randomised controlled trials (RCTs) and three cohort studies showed no additional benefit of treatment with vitamin K antagonists at target international normalised ratio (INR) 3-4 versus INR 2-3 in patients with venous thrombosis. In patients with arterial thrombosis, two RCTs and two cohort studies showed no difference in risk of recurrent thrombosis between the two target INR groups. One open-label trial showed higher rates of thrombosis recurrences in triple aPL-positive patients treated with rivaroxaban than those treated with warfarin. RCTs and cohort studies showed that combination treatment with LDA and heparin was more effective than LDA alone in several types of obstetric APS. SLR results were limited by the indirect evidence and the heterogeneity of patient groups for some treatments, and only a few high-quality RCTs. CONCLUSION: Well-designed studies of homogeneous APS patient populations are needed.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tektonidou MG, Andreoli L, Limper M, et al. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019. PMID: 31168416. doi:10.1136/rmdopen-2019-000924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。